Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.

Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.

Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Villavicencio H; 25 Urology Units, Asociación Española de Urología, Cantalapiedra A, Pedrosa E.

BJU Int. 2012 Dec;110(11 Pt B):E701-6. doi: 10.1111/j.1464-410X.2012.11504.x. Epub 2012 Sep 19.

2.

[National prostate cancer registry 2010 in Spain].

Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Villavicencio H, Cantalapiedra A, Pedrosa E.

Actas Urol Esp. 2013 Jan;37(1):12-9. doi: 10.1016/j.acuro.2012.06.006. Epub 2012 Oct 26. Spanish.

PMID:
23102541
3.

[Epidemiological trends in prostate cancer over the last years].

Luján Galán M, Páez Borda A, Chiva Robles V, Santonja Garriga C, Romero Cajigal I, Berenguer Sánchez A.

Arch Esp Urol. 2004 Oct;57(8):817-25. Spanish.

PMID:
15560270
4.

The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.

Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Hugosson J, Lundgren R, Stattin P, Törnblom M, Johansson JE.

Scand J Urol Nephrol. 2005;39(2):117-23.

PMID:
16019764
5.

Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.

Bratt O, Berglund A, Adolfsson J, Johansson JE, Törnblom M, Stattin P; Steering Committee of the Swedish National Prostate Cancer Register.

Scand J Urol Nephrol. 2010 Dec;44(6):384-90. doi: 10.3109/00365599.2010.498793. Epub 2010 Jul 13.

PMID:
20624113
6.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

7.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

8.

Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P.

Eur Urol. 2013 Jan;63(1):88-96. doi: 10.1016/j.eururo.2012.08.001. Epub 2012 Aug 10.

PMID:
22902040
9.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].

Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E.

Arch Esp Urol. 2005 Jun;58(5):403-11. Spanish.

PMID:
16078781
10.

Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.

Ladjevardi S, Berglund A, Varenhorst E, Bratt O, Widmark A, Sandblom G.

BJU Int. 2013 Mar;111(3):381-8. doi: 10.1111/j.1464-410X.2012.11320.x. Epub 2012 Jul 3.

11.

Towards an optimal interval for prostate cancer screening.

van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.

Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10.

PMID:
21840117
12.

Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.

Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P.

Eur Urol. 2011 Sep;60(3):554-63. doi: 10.1016/j.eururo.2011.05.047. Epub 2011 Jun 1.

PMID:
21664039
13.

Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.

Tonita JM, Skarsgard D, Muhajarine N.

Cancer Causes Control. 2009 Mar;20(2):201-9. doi: 10.1007/s10552-008-9234-6. Epub 2008 Sep 30.

PMID:
18825504
14.

Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.

Pilebro B, Johansson R, Damber L, Damber JE, Stattin P.

Scand J Urol Nephrol. 2003;37(3):210-2.

PMID:
12775278
15.

Clinical and histopathological characteristics of familial prostate cancer in Finland.

Pakkanen S, Kujala PM, Ha N, Matikainen MP, Schleutker J, Tammela TL.

BJU Int. 2012 Feb;109(4):557-63. doi: 10.1111/j.1464-410X.2011.10198.x. Epub 2011 Apr 20.

16.

Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.

Ranasinghe WK, Kim SP, Lawrentschuk N, Sengupta S, Hounsome L, Barber J, Jones R, Davis P, Bolton D, Persad R.

BJU Int. 2014 Jan;113(1):77-83. doi: 10.1111/bju.12354. Epub 2013 Oct 31.

17.

Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.

Stattin P, Johansson R, Damber JE, Hellström M, Hugosson J, Lundgren R, Varenhorst E, Johansson JE.

Scand J Urol Nephrol. 2003;37(6):461-5.

PMID:
14675917
18.

Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.

PMID:
21601352
19.

Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.

García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A.

BJU Int. 2012 Dec;110(11 Pt B):E541-6. doi: 10.1111/j.1464-410X.2012.11232.x. Epub 2012 May 15.

20.

The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.

Liang Y, Ketchum NS, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR.

Urol Int. 2012;89(1):9-16. doi: 10.1159/000338270. Epub 2012 May 24.

PMID:
22626812

Supplemental Content

Support Center